» Articles » PMID: 32952596

Nanoceria As a Possible Agent for the Management of COVID-19

Overview
Journal Nano Today
Specialty Biotechnology
Date 2020 Sep 21
PMID 32952596
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

The COVID-19 pandemic has emerged as an unprecedented global healthcare emergency and has devastated the global economy. The SARS-CoV-2 virus replicates in the host cells and is seemingly much more virulent compared to other flu viruses, as well as the SARS-CoV-1. The respiratory complications of the disease include acute respiratory distress syndrome (ARDS), cytokine storm, systemic inflammation, and pulmonary fibrosis. Nanoceria (NC) is a versatile rare earth nanoparticle with remarkable catalase and superoxide dismutase mimetic redox regenerative properties. Interestingly, NC possesses promising anti-inflammatory, antioxidant and anti-fibrotic properties, making it an attractive tool to fight against the SARS-CoV-2 as well as the associated systemic complications. Until now, there is no clinically approved vaccine or drug for the treatment of COVID-19, and the conquest to find a novel therapy for this global havoc is being undertaken at a warlike pace. Herein, based on preclinical evidence, we hypothesize that NC owing to its unique pharmacological properties, might be an attractive preclinical candidate to win the battle over COVID-19. Further, it may be used as a prevention or treatment strategy in combination with other drugs.

Citing Articles

Inhalable nanocatalytic therapeutics for viral pneumonia.

Peng W, Tai W, Li B, Wang H, Wang T, Guo S Nat Mater. 2024; .

PMID: 39592721 DOI: 10.1038/s41563-024-02041-5.


Nucleic acid-based nanotherapeutics for treating sepsis and associated organ injuries.

Yu H, Liu F, Chung Y, Alalaiwe A, Sung C, Fang J Theranostics. 2024; 14(11):4411-4437.

PMID: 39113804 PMC: 11303080. DOI: 10.7150/thno.98487.


Ce-based solid-phase catalysts for phosphate hydrolysis as new tools for next-generation nanoarchitectonics.

Komiyama M Sci Technol Adv Mater. 2023; 24(1):2250705.

PMID: 37701758 PMC: 10494760. DOI: 10.1080/14686996.2023.2250705.


Antimicrobial and anti-viral effects of selenium nanoparticles and selenoprotein based strategies: COVID-19 and beyond.

Khurana A, Allawadhi P, Singh V, Khurana I, Yadav P, Sathua K J Drug Deliv Sci Technol. 2023; 86:104663.

PMID: 37362903 PMC: 10249347. DOI: 10.1016/j.jddst.2023.104663.


Nano-based techniques: A revolutionary approach to prevent covid-19 and enhancing human awareness.

Annamalai A, Karuppaiya V, Ezhumalai D, Cheruparambath P, Balakrishnan K, Venkatesan A J Drug Deliv Sci Technol. 2023; 86:104567.

PMID: 37313114 PMC: 10183109. DOI: 10.1016/j.jddst.2023.104567.


References
1.
Selvaraj V, Nepal N, Rogers S, Manne N, Arvapalli R, Rice K . Inhibition of MAP kinase/NF-kB mediated signaling and attenuation of lipopolysaccharide induced severe sepsis by cerium oxide nanoparticles. Biomaterials. 2015; 59:160-71. PMC: 4565726. DOI: 10.1016/j.biomaterials.2015.04.025. View

2.
Estevez A, Pritchard S, Harper K, Aston J, Lynch A, Lucky J . Neuroprotective mechanisms of cerium oxide nanoparticles in a mouse hippocampal brain slice model of ischemia. Free Radic Biol Med. 2011; 51(6):1155-63. DOI: 10.1016/j.freeradbiomed.2011.06.006. View

3.
Kumari P, Saifi M, Khurana A, Godugu C . Cardioprotective effects of nanoceria in a murine model of cardiac remodeling. J Trace Elem Med Biol. 2018; 50:198-208. DOI: 10.1016/j.jtemb.2018.07.011. View

4.
Orienti I, Gentilomi G, Farruggia G . Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19. Int J Mol Sci. 2020; 21(11). PMC: 7312074. DOI: 10.3390/ijms21113812. View

5.
Chanda D, Otoupalova E, Smith S, Volckaert T, De Langhe S, Thannickal V . Developmental pathways in the pathogenesis of lung fibrosis. Mol Aspects Med. 2018; 65:56-69. PMC: 6374163. DOI: 10.1016/j.mam.2018.08.004. View